Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas Report on Five Patients and a Review of the Literature

被引：18

作者：

Amant, Frederic ^{[1
]}

Coosemans, An

Renard, Vincent ^{[2
]}

Everaert, Els

Vergote, Ignace

机构：

[1] Katholieke Univ Leuven, UZ Gasthuisberg, Dept Obstet & Gynecol, Div Gynecol Oncol,Leuven Canc Inst LKI, B-3000 Louvain, Belgium

[2] St Lucas Ziekenhuis Gent, Dept Med Oncol, Ghent, Belgium

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2009年 / 19卷 / 02期

关键词：

Uterine; Leiomyosarcoma; Yondelis; ET-743; Trabectedin; Sarcoma; SOFT-TISSUE SARCOMAS; PHASE-II TRIAL; SOLID TUMORS; ECTEINASCIDIN-743; LEIOMYOSARCOMA; GEMCITABINE; DOCETAXEL;

D O I：

10.1111/IGC.0b013e31819c0f59

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and Undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which I had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of I I patients with a clinical benefit in 7 (64%) of I I patients. These results on the Use of ET-743 in uterine sarcoma patients support the conductance of larger trials.

引用

页码：245 / 248

页数：4

共 14 条

[1] Transition of endometrial stromal sarcoma into high-grade sarcoma [J].

Amant, Frederic ;

Woestenborghs, Heidi ;

Vandenbroucke, Vanessa ;

Berteloot, Patrick ;

Neven, Patrick ;

Moerman, Philippe ;

Vergote, Ignace .

GYNECOLOGIC ONCOLOGY, 2006, 103 (03) :1137-1140

[2] Par-1 kinase establishes cell polarity and functions in Notch signaling in the Drosophila embryo [J].

Bayraktar, J ;

Zygmunt, D ;

Carthew, RW .

JOURNAL OF CELL SCIENCE, 2006, 119 (04) :711-721

[3] Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study [J].

Garcia-Carbonero, R ;

Supko, JG ;

Maki, RG ;

Manola, J ;

Ryan, DP ;

Harmon, D ;

Puchalski, TA ;

Goss, G ;

Seiden, MV ;

Waxman, A ;

Quigley, MT ;

Lopez, T ;

Sancho, MA ;

Limeno, J ;

Guzman, C ;

Demetri, GD .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5484-5492

[4] Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial [J].

Hensley, ML ;

Maki, R ;

Venkatraman, E ;

Geller, G ;

Lovegren, M ;

Aghajanian, C ;

Sabbatini, P ;

Tong, W ;

Barakat, R ;

Spriggs, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2824-2831

[5] Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial [J].

Le Cesne, A ;

Blay, JY ;

Judson, I ;

Van Oosterom, A ;

Verweij, J ;

Radford, J ;

Lorigan, P ;

Rodenhuis, S ;

Ray-Coquard, I ;

Bonvalot, S ;

Collin, F ;

Jimeno, J ;

Di Paola, E ;

Van Glabbeke, M ;

Nielsen, OS .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :576-584

[6] High-dose epirubicin in patients with advanced or recurrent uterine sarcoma [J].

Lissoni, A ;

Cormio, G ;

Colombo, N ;

Gabriele, A ;

Landoni, F ;

Zanetta, G ;

Mangioni, C .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1997, 7 (03) :241-244

[7] Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas [J].

Maki, Robert G. ;

Wathen, J. Kyle ;

Patel, Shreyaskumar R. ;

Priebat, Dennis A. ;

Okuno, Scott H. ;

Samuels, Brian ;

Fanucchi, Michael ;

Harmon, David C. ;

Schuetze, Scott M. ;

Reinke, Denise ;

Thall, Peter F. ;

Benjamin, Robert S. ;

Baker, Laurence H. ;

Hensley, Martee L. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2755-2763

[8]

OMURA GA, 1983, CANCER-AM CANCER SOC, V52, P626, DOI 10.1002/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO

[9]

2-E

[10] PHASE-II TRIAL OF IFOSFAMIDE AND MESNA IN LEIOMYOSARCOMA OF THE UTERUS - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].

SUTTON, GP ;

BLESSING, JA ;

BARRETT, RJ ;

MCGEHEE, R .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (02) :556-559

← 1 2 →